The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Matzim® LA (Diltiazem Hydrochloride) Extended-Release Tablets

| NDC              | Lot #    | Exp. Date | Strength | Size | Dates Distributed          |
|------------------|----------|-----------|----------|------|----------------------------|
| 52544-691-<br>30 | 1411593A | 09/2022   | 11X() mg |      | 12/02/2020 -<br>12/30/2020 |
| 52544-692-<br>30 | 1411596A | 09/2022   | 240 mg   |      | 12/04/2020 -<br>01/06/2021 |

Teva Pharmaceuticals USA Inc. (Teva USA) is initiating a recall of the above drug product lots to the Retail Level. The subject product lots are packaged and distributed under label of Actavis Pharma Inc.

This recall is being initiated because of a recent stability result for dissolution testing of lot 1411596A, which is below specification limits, and lot 1411593A is trending towards this out of specification at its expiration.